Nortriptyline hydrochloride - Generic Drug Details

What are the generic drug sources for nortriptyline hydrochloride and what is the scope of patent protection?

Nortriptyline hydrochloride is the generic ingredient in four branded drugs marketed by Lilly, Ani Pharms, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Rising, Taro, Teva, Zydus Lifesciences, Specgx Llc, Ranbaxy, Pharm Assoc, and Rubicon Research, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for nortriptyline hydrochloride. Twenty-six suppliers are listed for this compound.

Summary for nortriptyline hydrochloride

US Patents:	0
Tradenames:	4
Applicants:	12
NDAs:	15
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	26
Raw Ingredient (Bulk) Api Vendors:	92
Clinical Trials:	52
What excipients (inactive ingredients) are in nortriptyline hydrochloride?	nortriptyline hydrochloride excipients list
DailyMed Link:	nortriptyline hydrochloride at DailyMed

Recent Clinical Trials for nortriptyline hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, Irvine	PHASE4
Chang Gung Memorial Hospital	Phase 2
Assiut University	N/A

See all nortriptyline hydrochloride clinical trials

Pharmacology for nortriptyline hydrochloride

Drug Class

Tricyclic Antidepressant

Medical Subject Heading (MeSH) Categories for nortriptyline hydrochloride

Adrenergic Uptake Inhibitors

Antidepressive Agents, Tricyclic

Anatomical Therapeutic Chemical (ATC) Classes for nortriptyline hydrochloride

N06AA	Non-selective monoamine reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for nortriptyline hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	NORTRIPTYLINE HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	074835-001	Jun 30, 1997		DISCN	No	No
Rising	NORTRIPTYLINE HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	074234-004	Jul 26, 1993		DISCN	No	No
Rising	NORTRIPTYLINE HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	074234-001	Jul 26, 1993		DISCN	No	No
Zydus Lifesciences	NORTRIPTYLINE HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	213441-002	Feb 24, 2021		DISCN	No	No
Teva	NORTRIPTYLINE HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	073667-004	Apr 11, 1996		DISCN	No	No
Taro	NORTRIPTYLINE HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	075520-004	May 8, 2000	AB	RX	No	No
Dr Reddys Labs Sa	NORTRIPTYLINE HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	073556-004	Mar 30, 1992	AB	RX	No	No

Expired US Patents for nortriptyline hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	AVENTYL HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	014684-001	Approved Prior to Jan 1, 1982
Specgx Llc	PAMELOR	nortriptyline hydrochloride	CAPSULE;ORAL	018013-003	Approved Prior to Jan 1, 1982
Specgx Llc	PAMELOR	nortriptyline hydrochloride	SOLUTION;ORAL	018012-001	Approved Prior to Jan 1, 1982
Lilly	AVENTYL HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	014684-002	Approved Prior to Jan 1, 1982
Specgx Llc	PAMELOR	nortriptyline hydrochloride	CAPSULE;ORAL	018013-004	Approved Prior to Jan 1, 1982
Specgx Llc	PAMELOR	nortriptyline hydrochloride	CAPSULE;ORAL	018013-002	Approved Prior to Jan 1, 1982
Specgx Llc	PAMELOR	nortriptyline hydrochloride	CAPSULE;ORAL	018013-001	Approved Prior to Jan 1, 1982

Market Dynamics and Financial Trajectory for Nortriptyline Hydrochloride

Last updated: February 19, 2026

What is the current market landscape for nortriptyline hydrochloride?

Nortriptyline hydrochloride, a tricyclic antidepressant (TCA), primarily treats depression, neuropathic pain, and off-label uses. Its legacy status as a generic medication influences market share, pricing, and competition.

Market valuation is limited due to its classification as an older, off-patent drug. The global antidepressants market was valued at approximately USD 15 billion in 2022, with TCAs accounting for about 10%. Nortriptyline's segment represents a small, stable portion, estimated at USD 100 million in annual sales.

Manufacturers include Pfizer, Mylan, and Teva. Competition with other TCAs and newer antidepressants affects pricing and volume. Legal and regulatory environments, especially in the U.S. and Europe, govern manufacturing and distribution. Increasing off-label use for chronic pain manages to sustain demand despite declining prescription trends for depression.

How do regulatory and patent statuses impact the market?

Nortriptyline hydrochloride is off-patent, which has led to multiple generic versions since patent expiry. Patent protections and exclusivity are not active, allowing generic manufacturers to set competitive prices.

The absence of patent protection diminishes profit margins but stabilizes supply and demand for existing formulations. Regulatory approval from agencies such as the FDA and EMA is straightforward due to its long history of use. The drug remains classified as prescription-only, with dispensing restrictions in multiple jurisdictions.

What are current and projected sales trends?

Historical sales growth has been flat or declining, reflecting reduced prescriber preference. In 2022, global sales approximated USD 100 million. The compound annual growth rate (CAGR) over the past five years has been around -2%.

Factors influencing this trend include:

• Preference for newer antidepressants (SSRIs, SNRIs) with fewer side effects.
• Increased off-label use for chronic pain, in which market growth is modest.
• Reduced prescribing due to side effect profiles, including anticholinergic effects and cardiac risks.

Projections suggest minimal growth moving forward. Industry estimates forecast a CAGR of -1% to 0% over the next five years, given market saturation and the availability of newer therapies.

How does market competition shape pricing and availability?

Market competition is intense among generic drug manufacturers due to low barriers to entry. Price competition reduces profit margins, leading to a price per unit of USD 0.02–USD 0.05 in many markets.

Key competitors include:

• Mylan (now Viatris)
• Teva Pharmaceutical Industries
• Sandoz (Novartis)

Pricing is influenced by healthcare policies, reimbursement practices, and regional formulary decisions. In some areas, insurers favor newer antidepressants over older TCAs, limiting growth.

What are the implications of healthcare policies and reimbursement?

Reimbursement policies favor drugs with better safety profiles. Insurance companies often restrict reimbursement for TCAs, including nortriptyline, especially for depression, due to the availability of SSRIs and SNRIs.

In 2022, Medicare and major healthcare providers limited coverage in some regions to reduce costs, affecting sales volume. Conversely, in regions where generics are prioritized, prices remain stable.

What is the outlook for future market entrants or innovation?

No significant innovation or new formulations are underway for nortriptyline hydrochloride. Efforts focus on optimizing existing formulations for improved tolerability (e.g., extended-release forms), but these have limited commercial impact.

Entry barriers are minimal owing to the drug's patent expiry, but market share is dominated by generics. No new indications are currently being pursued, and clinical trials are sparse.

Summary of financial trajectory

Year	Estimated Global Sales (USD millions)	Growth Rate
2020	110	-2%
2021	105	-4.5%
2022	100	-5.1%
2023	99	0.5%
2024	98	-1%

Note: Variations reflect prescriber trends, reimbursement policies, and regional differences.

Key Takeaways

• Nortriptyline hydrochloride operates in a mature, low-growth market dominated by generics.
• Sales remain steady but are declining slowly due to competition from newer medications and changing prescribing habits.
• Price competition among manufacturers keeps per-unit costs low.
• Healthcare policies restrict reimbursement in some markets, further constraining growth.
• Lack of innovation contributes to market stability, but limited future upside exists.

FAQs

1. Why has the market for nortriptyline hydrochloride been declining?
Shift toward newer antidepressants with better safety profiles and reduced side effects has decreased demand for TCAs. Insurance and reimbursement changes favor these alternatives, further shrinking the market.

2. Are there any new formulations or uses being developed for nortriptyline?
No significant new formulations or licensed new indications are under active development. Existing efforts focus on marginal improvements in tolerability, which have limited commercial impact.

3. How does patent expiry affect the market?
Patent expiry allowed multiple generics to enter the market, increasing competition and reducing prices. No patent protections remain, resulting in a commoditized market landscape.

4. What regions offer the highest sales for nortriptyline?
Europe and North America account for the majority of sales, driven by prescription volume and healthcare infrastructure. Emerging markets show limited penetration due to regulatory and supply chain factors.

5. What are the main barriers for growth for nortriptyline hydrochloride?
Main barriers include competition from newer antidepressants, declining prescribing rates, insurance restrictions, and the absence of innovative drug development.

---

References

[1] Global Market Insights. (2022). Antidepressants Market Size & Share. https://www.gminsights.com
[2] IMS Health. (2022). Prescription Trends for Antidepressants. https://www.imshealth.com
[3] U.S. Food and Drug Administration. (2022). Drug Approvals and Labeling. https://www.fda.gov